Adicet Bio
ACET
39 hedge funds and large institutions have $107M invested in Adicet Bio in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
41.48% more ownership
Funds ownership: 0% → 41.48% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$79.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.1M |
| 3 |
Jennison Associates
New York
|
+$13.4M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$9.01M |
| 5 |
AG
Artal Group
Luxembourg
|
+$7.37M |
Top Sellers
ACET Hedge Fund Activity: Q1 2018 in Review
39 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2018, worth a combined $107M.
Buyers outnumbered sellers: 39 funds opened new ACET positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $79.1M.
- 39 institutional investors held Adicet Bio (ACET) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $107M of Adicet Bio stock for Q1 2018.
- 39 funds opened new Adicet Bio positions in Q1 2018 and 0 closed out, a net change of +39 holders.
- The largest Adicet Bio buyer in Q1 2018 was OrbiMed, an estimated $79.1M added.
Based on aggregated 13F filings for Q1 2018.